A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HS-10380 in Chinese Healthy Adult Subjects
Latest Information Update: 10 Mar 2023
At a glance
- Drugs HS-10380 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Jiangsu Hansoh Pharmaceutical
Most Recent Events
- 07 Mar 2023 Planned End Date changed from 30 Jan 2023 to 30 Jul 2023.
- 07 Mar 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Jun 2023.
- 29 Aug 2022 Status changed from not yet recruiting to recruiting.